Market Snapshot
  • U.S.
  • Europe
  • Asia
Ticker Volume Price Price Delta
DJIA 16,408.54 -16.31 -0.10%
S&P 500 1,864.85 2.54 0.14%
NASDAQ 4,095.52 9.29 0.23%
Ticker Volume Price Price Delta
STOXX 50 3,155.81 16.55 0.53%
FTSE 100 6,625.25 41.08 0.62%
DAX 9,409.71 91.89 0.99%
Ticker Volume Price Price Delta
NIKKEI 14,516.27 98.74 0.68%
TOPIX 1,173.37 6.78 0.58%
HANG SENG 22,760.24 64.23 0.28%

Perrigo Announces Launch of Authorized Generic Version of Acetadote® (acetylcysteine) Injection



     Perrigo Announces Launch of Authorized Generic Version of Acetadote®
                          (acetylcysteine) Injection

PR Newswire

ALLEGAN, Mich., Jan. 7, 2013

ALLEGAN, Mich., Jan. 7, 2013 /PRNewswire/ -- Perrigo Company (Nasdaq: PRGO;
TASE) today announced that it has made initial shipments distributing
Cumberland Pharmaceuticals Inc.'s ("Cumberland") Authorized Generic form of
Acetadote® (acetylcysteine) injection. The Authorized Generic is free of EDTA
and any other chelating, stabilization or preservative agents.

(Logo:  http://photos.prnewswire.com/prnh/20120301/DE62255LOGO)

On November 13, 2012, Perrigo announced that it and Cumberland had
successfully settled their patent litigation. In addition, Perrigo secured the
right to be a distributor should Cumberland elect to launch an Authorized
Generic acetylcysteine injection product. 

Acetadote® (acetylcysteine) injection, administered intravenously within 8 to
10 hours after ingestion of a potentially hepatotoxic quantity of
acetaminophen, is indicated to prevent or lessen hepatic injury and has annual
sales of approximately $41 million, as measured by Symphony Health Solutions.

Perrigo's Chairman, President and CEO Joseph C. Papa stated, "This is another
example of Perrigo's commitment to bring new products to market. Perrigo
continues to deliver on its mission to provide quality, affordable healthcare
to consumers."

From its beginnings as a packager of generic home remedies in 1887, Perrigo
Company, based in Allegan, Michigan, has grown to become a leading global
provider of quality, affordable healthcare products. The Company develops,
manufactures and distributes over-the-counter ("OTC") and generic prescription
("Rx") pharmaceuticals, nutritional products and active pharmaceutical
ingredients ("API") and is the world's largest manufacturer of OTC
pharmaceutical products for the store brand market. Perrigo's mission is to
offer uncompromised "quality, affordable healthcare products", and it does so
across a wide variety of product categories primarily in the United States,
United Kingdom, Mexico, Israel and Australia, as well as certain other markets
throughout the world, including Canada, China and Latin America. Visit Perrigo
on the Internet (http://www.perrigo.com).

Note: Certain statements in this press release are forward-looking statements
within the meaning of Section 21E of the Securities Exchange Act of 1934, as
amended, and are subject to the safe harbor created thereby. These statements
relate to future events or the Company's future financial performance and
involve known and unknown risks, uncertainties and other factors that may
cause the actual results, levels of activity, performance or achievements of
the Company or its industry to be materially different from those expressed or
implied by any forward-looking statements. In some cases, forward-looking
statements can be identified by terminology such as "may," "will," "could,"
"would," "should," "expect," "plan," "anticipate," "intend," "believe,"
"estimate," "predict," "potential" or other comparable terminology. The
Company has based these forward-looking statements on its current
expectations, assumptions, estimates and projections.  While the Company
believes these expectations, assumptions, estimates and projections are
reasonable, such forward-looking statements are only predictions and involve
known and unknown risks and uncertainties, many of which are beyond the
Company's control. These and other important factors, including those
discussed under "Risk Factors" in the Company's Form 10-K for the year ended
June 30, 2012, as well as the Company's subsequent filings with the Securities
and Exchange Commission, may cause actual results, performance or achievements
to differ materially from those expressed or implied by these forward-looking
statements. The forward-looking statements in this press release are made only
as of the date hereof, and unless otherwise required by applicable securities
laws, the Company disclaims any intention or obligation to update or revise
any forward-looking statements, whether as a result of new information, future
events or otherwise.

SOURCE Perrigo Company

Website: http://www.perrigo.com
Contact: Arthur J. Shannon, Vice President, Investor Relations and
Communication, +1-269-686-1709, ajshannon@perrigo.com; Bradley Joseph, Senior
Manager, Investor Relations and Communication, +1-269-686-3373,
bradley.joseph@perrigo.com
Sponsored Links
Advertisement
Advertisements
Sponsored Links
Advertisement